Product Description
CRB-601 is a potent and selective alphavb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. (Sourced from: https://www.corbuspharma.com/press-releases/detail/368/corbus-presents-first-preclinical-data-for-crb-601-at-the)
Mechanisms of Action: aVb8 Antagonist
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Corbus
Company Location: NORWOOD MA 02062
Company CEO: Yuval Cohen
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United Kingdom, United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Expected - Corbus announced they will present P1 Oncology Solid Tumor Unspecified results in 4Q25 for CRB-601
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CRB-601-01 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2026-11-01 |
12% |
2025-06-04 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
06/30/2025 |
News Article |
Corbus Pharmaceuticals Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted CB1 Inverse Agonist CRB-913 for the Treatment of Obesity |
|
06/25/2025 |
News Article |
Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab |
|
06/24/2025 |
News Article |
Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium |
|
05/22/2025 |
News Article |
Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference |